How FDA Facility Inspection Outcomes Shape NDA and BLA Approvals

How FDA facility inspection outcomes shape NDA and BLA approvals

For a new drug or biologic, clinical efficacy and safety are only half of the approval equation. The other half is whether the establishments named in the application can actually make the product under current good manufacturing practice (CGMP). FDA answers that question through the preapproval inspection (PAI) program, and the inspectional outcome feeds directly into the marketing decision. A pending NDA, ANDA, or BLA cannot be approved while a required facility is in an unacceptable state, and Form FDA 483 observations, an Official Action Indicated (OAI) classification, or a facility "withhold" recommendation routinely convert into a Complete Response Letter (CRL) or a slipped action date. This article walks through the mechanism and the documented precedent.

The preapproval inspection is part of the application review, not a side process

When a marketing application is submitted, CDER's Office of Program and Regulatory Operations (OPMA) opens a preapproval facility evaluation. An Integrated Quality Assessment (IQA) team weighs application and facility risk to decide whether an on-site PAI is warranted. If it is, ORA leads the inspection with CDER participation, and the inspection findings, the Establishment Inspection Report (EIR), the Form FDA 483, and the firm's responses are then used together to decide whether the facility is acceptable for that specific pending application ⁶⁵⁶⁶⁷⁰⁷²⁵³⁶⁷⁷⁴.

The program is built around a defined set of PAI objectives ⁷⁰⁶⁴:

Readiness for commercial manufacturing ⁶⁰⁶¹⁷⁰
Conformance to application (does the site actually operate as the dossier describes?) ⁶⁰⁶¹⁷⁰
Data integrity audit ⁷⁰⁶⁴
A fourth objective, commitment to quality in pharmaceutical development, is also listed ⁷⁰⁶⁴

The point for regulatory strategy is that the facility assessment runs in parallel with the clinical and CMC review. Assessors make initial approvability judgments while the inspection is still in progress, and those judgments are modified once the inspection outcome is known ¹.

Acceptable versus withhold: the recommendation that gates approval

Each covered facility receives an acceptable/approve or a withhold recommendation. An acceptable recommendation is made when there are no significant issues, or none of the withhold criteria apply ⁵⁷⁵⁹⁵⁵⁶⁷. A withhold recommendation is made when significant deficiencies would adversely affect the establishment's ability to perform the functions described in the application, or when significant data integrity problems are observed ⁵⁷⁵⁹⁵⁵⁸².

The program lists specific conditions that support a withhold recommendation, including ⁵⁷⁵⁹⁵²⁸²⁸⁷:

Significant data integrity problems, including misrepresented data or submission-batch problems
Serious CGMP concerns with biobatches, pivotal clinical, exhibit, or validation batches
Lack of complete manufacturing and control instructions, or lack of data supporting them
Lack of capacity to manufacture the product or API, or the firm not being ready for inspection
Failure to meet application commitments, or the firm not performing the functions listed in the application
Failed full-scale process performance qualification (PPQ) showing the process is not under control
Incomplete or unsuccessful analytical method validation or verification
Significant stability failures, failure to report failing data, or delaying/denying/limiting/refusing an inspection

When one or more quality systems are documented as not in a state of control, the inspection is endorsed as OAI (Official Action Indicated) ⁸⁸, the classification that signals a facility is not presently acceptable. There is one notable guardrail: for NDAs and ANDAs, FDA will not issue a withhold recommendation solely because full commercial-scale process validation is incomplete at the time of the PAI ⁵²⁵⁴.

The withhold recommendation is not an informal note. The ORA assessor emails the decision to withhold, with the Form FDA 483 attached, to the CDER PAI program mailbox as soon as possible; in the biologics program the inspection team lead communicates findings within two business days and routes the initial field recommendation and 483 to OPMA leadership ⁵⁵⁸⁹. The review office then evaluates the EIR, 483, and firm responses and issues the final concurrence through the agency's informatics workflow ⁵²⁵⁴⁶⁷⁵³.

What happens to a pending application when a required facility is OAI

CDER integrates the inspection outcome into the approval decision rather than treating it as a separate clearance. OPQ assessors evaluate completed inspection information on CGMP compliance and pharmaceutical quality system (PQS) effectiveness, and those findings inform whether the application is approvable ³⁵⁷. Where residual PQS risk or pending remediation exists, including in an OAI-to-VAI transition, OPMA/OQS consult the Office of Compliance before proceeding ⁶. Reclassification or post-approval flexibility requests tied to facility deficiencies are only granted once the facility issues are addressed (for example, once the site is NAI or the deficiencies are resolved); otherwise they are denied ¹⁰¹²²³.

In practice, an unresolved OAI or "unacceptable" facility recommendation on a required establishment means the quality side of the review is not approvable, and the application receives a Complete Response until the deficiencies are corrected and, where necessary, verified by reinspection ⁵²⁵⁴⁶⁷. The clearest evidence of this is in FDA's own review memoranda and CRLs.

CRL precedent: facility deficiencies as the stated basis for non-approval

Complete Response Letters repeatedly cite manufacturing and facility problems as the reason an application could not be approved. The recurring buckets are (1) observed CGMP deficiencies at a named site, (2) a required inspection that could not be completed, (3) a facility that was not ready for inspection, and (4) data reliability concerns tied to a manufacturing site.

Product / application	Company	Facility issue cited in the CRL
Furoscix, NDA 209988	scPharmaceuticals	Recent inspection found deficiencies requiring satisfactory resolution; Sharp Corporation site also needed inspection before approval ¹⁸⁹
NexoBrid / BLA 761192	MediWound	Challenge Bioproducts and MediWound drug-substance/product sites required CGMP assessment before approval ¹⁹⁰
NDA 210136	Braeburn	Deficiencies conveyed during inspection of Pharmaceutics International (Pii), Hunt Valley, to be resolved before approval ¹⁹¹
Cantharidin 7% topical, NDA 212905	Verrica	Facility "not ready for inspection"; satisfactory inspection required before approval ¹⁹³
DEXTENZA, NDA 208742	Ocular Therapeutix	Manufacturing facility deficiencies observed during a recent inspection required resolution ²⁰⁸
Cystadrops, NDA 211302	Recordati Rare Diseases	Baccinex SA CGMP noncompliance; all sites had to be CGMP-compliant before approval ²⁰⁹
NDA 211039	Bausch Health Ireland	Methods, facilities, and controls did not comply with CGMP; objectionable conditions observed ²⁰¹
NDA 205508	Heritage / Avet	Original drug-product site generated "potentially unreliable" data, undermining bioequivalence support ²⁰⁴
NORLIQVA, NDA 214439	CMP Development	Recent inspection found deficiencies and objectionable conditions; another inspection required before approval ²¹²
BLA 761184	Pfizer Ireland	Dublin and Pfizer Manufacturing Belgium sites required CGMP inspection before approval ¹⁹⁵

FDA's language is strikingly consistent. In the Furoscix CRL the agency wrote that its investigator "conveyed deficiencies" and that "satisfactory resolution of these deficiencies is required before this application may be approved" ¹⁸⁹. For CELLTRION's BLA 761377 and Telix's BLA 761401, FDA stated it "may determine that a CGMP reinspection and/or additional PLI [or PAI] is needed to confirm satisfactory resolution of inspection deficiencies before this application can be approved" ²¹⁴²¹⁶. A single 483 observation set, left unresolved, is therefore sufficient to hold a BLA.

The inspection that never happened is also an approval bar

A distinct and heavily litigated pattern, prominent during the pandemic-era travel restrictions, is the application blocked not by an adverse finding but by an incomplete or unconducted inspection. FDA treated the missing inspection itself as an approvability barrier.

Across CRLs for MediWound (BLA 761192), Chiesi's BLA 761161 (Protalix, Carmiel, Israel), Rovi (NDA 214835, Spain), and Nobelpharma (NDA 213478, Toyo Pharmaceutical), FDA used near-identical wording: "Due to restrictions on travel, we were unable to conduct an inspection during the current review cycle," and, critically, "even if these deficiencies are addressed, the application cannot be approved until the required FDA inspection is conducted and any findings are assessed" ¹⁹⁰¹⁹⁹¹⁹⁸²²⁴. Where a site was simply not ready, FDA said so plainly, as with Verrica ("the facility was not ready for inspection") ¹⁹³, Belcher Pharmaceuticals (NDA 207987) ²²⁰, NorthStar Medical Radioisotopes (NDA 202158) ²¹⁷, and GeNO (NDA 202860) ²²¹. The practical lesson is that inspection readiness and access are gating items on the critical path, independent of whether the site would pass.

Data integrity findings and the Application Integrity Policy

Data integrity occupies a special tier. When a PAI or post-approval inspection surfaces a pattern of unreliable, inaccurate, incomplete, or manipulated data, FDA may escalate to the Application Integrity Policy (AIP), which can implicate every product made at a facility and cast doubt on the integrity of all information submitted ³⁴³⁶³⁹⁴⁸. Investigators are directed to document the unreliable data in the EIR, notify OPMA promptly so the impact on the application can be evaluated immediately, and, where the problem appears broad, expand the inspection to other products at the site ³⁴.

The AIP does not automatically refuse review of every pending application, but data-reliability concerns trigger an immediate assessment of the application's impact and can lead to AIP invocation or a for-cause inspection ³⁴³⁷. For serious electronic-records and signature deviations, FDA states it will not accept those records to meet predicate-rule requirements ⁴¹. The Heritage/Avet CRL (NDA 205508) is a concrete instance of the underlying logic: because the original manufacturing site's data were "potentially unreliable," the bioequivalence support was compromised and a new BE study at a new site was implicated ²⁰⁴.

Approval delays documented in FDA review memoranda

Review memos give the cleanest view of how a facility classification changes an action. Several show a Complete Response driven purely by the facility recommendation, and, in some cases, eventual approval only after reinspection reclassified the site:

INFUGEM (gemcitabine HCl), NDA 208313 — the drug-product site, Sun Pharmaceutical Industries, was OAI and received a withhold recommendation. It had been inspected in 2014, received a warning letter, was re-inspected in 2016 and remained OAI. The unresolved OAI status forced a Complete Response; approval followed only after a 2018 reinspection reclassified the site as VAI ¹⁰³¹⁰⁴¹⁰⁵.
Bortezomib for Injection, NDA 205004 — the Office of Process and Facilities did not recommend approval due to drug-product facility issues, and the NDA received a Complete Response on the facility withhold recommendation ¹⁰⁹.
Amphora vaginal gel, NDA 208352 (Evofem) — the inspection found "significant quality and CGMP deficiencies," the facility was not acceptable, and an overall withhold recommendation drove a Complete Response ¹¹⁴.
Dalvance (dalbavancin), NDA 21-883 — the drug-product site was cited for CGMP non-compliance, prompting an Office of Compliance withhold; the NDA was approvable only pending resolution of all outstanding CGMP issues ¹⁰⁸.
Caspofungin acetate, NDA 206110 — an "unacceptable" facility recommendation from the Office of Compliance drove a Complete Response until the facility deficiencies were resolved ¹¹⁵.
Argatroban in Sodium Chloride, NDA 209552 — originally Complete Response on a withhold recommendation; a later reinspection issued a 483 with a pOAI classification, and FDA required satisfactory resolution of all deficiencies before approval ¹¹¹.
Furoscix, NDA 209988 — the manufacturing recommendation was "Withhold" because a facility was OAI, described as an unacceptable CGMP state, and the NDA was not recommended for approval ¹¹⁶¹²⁰.
Hylenex Recombinant, BLA 21-859 — the contract drug-substance site (Avid Bioservices) had a pending CGMP status, which remained an unresolved barrier to approvability in the review package ¹¹².

What this means for regulatory planning

The precedent points to a few durable conclusions. First, every establishment named in an NDA or BLA, including contract and foreign sites and drug-substance intermediate manufacturers, is on the approval critical path; a withhold on any one required site holds the whole application ¹⁹⁰¹⁹⁸. Second, a facility "withhold" or OAI recommendation is functionally an approval stop, and it is communicated through a defined workflow that reaches the review division quickly, so 483 responses need to be substantive and fast ⁵⁵⁸⁹. Third, inspection readiness and access are gating items in their own right, and a site that is not ready, or that cannot be reached, will draw a CRL even absent an adverse finding ¹⁹³¹⁹⁸. Fourth, data integrity is the highest-risk finding, because it can trigger the Application Integrity Policy and contaminate confidence in the entire submission ³⁴³⁶. Finally, recovery is possible but cycle-costly: the INFUGEM and Argatroban histories show that OAI sites can be reclassified and applications ultimately approved, but only after remediation and reinspection, typically across a later review cycle ¹⁰³¹⁰⁵¹¹¹.

How FDA Facility Inspection Outcomes Shape NDA and BLA Approvals